Fluorouracil
- Generic Name
- Fluorouracil
- Brand Names
- Actikerall, Carac, Efudex, Fluoroplex, Tolak
- Drug Type
- Small Molecule
- Chemical Formula
- C4H3FN2O2
- CAS Number
- 51-21-8
- Unique Ingredient Identifier
- U3P01618RT
- Background
A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.
- Indication
For the topical treatment of multiple actinic or solar keratoses. In the 5% strength it is also useful in the treatment of superficial basal cell carcinomas when conventional methods are impractical, such as with multiple lesions or difficult treatment sites. Fluorouracil injection is indicated in the palliative management of some types of cancer, including ...
- Associated Conditions
- Actinic Keratosis (AK), Breast Cancer, Colon Cancer, Gastric Cancer, Pancreatic Cancer, Rectal Cancer, Superficial Basal Cell Carcinoma, Verruca (Warts), Hyperkeratotic actinic keratosis
- Associated Therapies
- -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 880
- Registration Number
- NCT00025337
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-01-10
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT00003799
- Locations
- 🇺🇸
Eastern Cooperative Oncology Group, Boston, Massachusetts, United States
Surgery Followed by Radiation Therapy and Chemotherapy in Treating Patients With Cancer of the Pancreas
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2016-12-22
- Lead Sponsor
- Mayo Clinic
- Target Recruit Count
- 100
- Registration Number
- NCT00003049
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2021-02-17
- Lead Sponsor
- UNICANCER
- Registration Number
- NCT00005979
- Locations
- 🇫🇷
Centre Hospitalier de Fleyriat, Bourg-En-Bresse, France
🇫🇷Centre Leon Berard, Lyon, France
🇫🇷Institut Bergonie, Bordeaux, France
Radiation Therapy Plus Celecoxib, Fluorouracil, and Cisplatin in Patients With Locally Advanced Cervical Cancer
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-11-19
- Lead Sponsor
- Radiation Therapy Oncology Group
- Target Recruit Count
- 84
- Registration Number
- NCT00023660
- Locations
- 🇺🇸
Akron General Medical Center, Akron, Ohio, United States
🇺🇸Akron City Hospital - Summa Health System, Akron, Ohio, United States
🇺🇸Western Pennsylvania Hospital, Pittsburgh, Pennsylvania, United States
Surgery With or Without Combination Chemotherapy in Treating Patients With Liver Metastases From Colorectal Cancer
- Conditions
- Locations
- 🇦🇺
Royal Perth Hospital, Perth, Western Australia, Australia
🇦🇺Mount Hospital, Perth, Western Australia, Australia
🇦🇺Frankston Hospital, Frankston, Victoria, Australia
A Phase I Trial of 5-Fluorouracil Given With 776C85 (GW776) and Low-Dose Leucovorin in Adult Patients With Solid Tumors
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2006-07-17
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 50
- Registration Number
- NCT00001579
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 55
- Registration Number
- NCT00001498
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
A Phase II Study of 5-Fluorouracil Administered as a One Hour Infusion in Combination With Calcium Leucovorin and Interferon Alpha-2A in Advanced Colorectal Cancer
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 65
- Registration Number
- NCT00001428
- Locations
- 🇺🇸
National Cancer Institute (NCI), Bethesda, Maryland, United States
Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
- Conditions
- First Posted Date
- 2002-09-06
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Wellstat Therapeutics
- Target Recruit Count
- 24
- Registration Number
- NCT00044785
- Locations
- 🇺🇸
University of Maryland, Greenebaum Cancer Center, Baltimore, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.